XML 31 R22.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue | 9 Months Ended
--- | ---
Sep. 30, 2021
Revenue [Abstract] |
REVENUE | 14. REVENUE We primarily offer the First Defense Ò product line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select international regions and may expand this international reach in the future. There were no material changes between the allocation and timing of revenue recognition during the three-month periods ended September 30, 2021 or 2020 or during the nine-month periods ended September 30, 2021 or 2020. We do not have any contract assets for which we have satisfied the performance obligations but do not yet have the right to bill for or contract liabilities such as customer advances. All trade receivables on our balance sheets are from contracts with customers. We incur no material costs to obtain contracts. The following table presents our product sales disaggregated by geographic area:
|  | During the Three-Month Periods Ended September 30, |  |  | During the Nine-Month Periods Ended September 30, |
|  | 2021 |  |  | % |  |  | 2020 |  |  | % |  |  | 2021 |  |  | % |  |  | 2020 |  |  | % |
United States |  | $ | 4,550,343 |  |  |  | 88 | % |  | $ | 3,361,820 |  |  |  | 90 | % |  | $ | 12,161,097 |  |  |  | 88 | % |  | $ | 10,319,232 |  |  |  | 89 | %
Other |  |  | 599,830 |  |  |  | 12 | % |  |  | 360,697 |  |  |  | 10 | % |  |  | 1,638,032 |  |  |  | 12 | % |  |  | 1,279,626 |  |  |  | 11 | %
Total Product Sales |  | $ | 5,150,173 |  |  |  | 100 | % |  | $ | 3,722,517 |  |  |  | 100 | % |  | $ | 13,799,129 |  |  |  | 100 | % |  | $ | 11,598,858 |  |  |  | 100 | %
The following table presents our product sales disaggregated by major product category:
|  | During the Three-Month Periods Ended September 30, |  |  | During the Nine-Month Periods Ended September 30, |
|  | 2021 |  |  | % |  |  | 2020 |  |  | % |  |  | 2021 |  |  | % |  |  | 2020 |  |  | % |
First Defense® product line |  | $ | 5,033,428 |  |  |  | 98 | % |  | $ | 3,656,709 |  |  |  | 98 | % |  | $ | 13,529,847 |  |  |  | 98 | % |  | $ | 11,406,481 |  |  |  | 98 | %
Other animal health |  |  | 116,745 |  |  |  | 2 | % |  |  | 65,808 |  |  |  | 2 | % |  |  | 269,282 |  |  |  | 2 | % |  |  | 192,377 |  |  |  | 2 | %
Total Product Sales |  | $ | 5,150,173 |  |  |  | 100 | % |  | $ | 3,722,517 |  |  |  | 100 | % |  | $ | 13,799,129 |  |  |  | 100 | % |  | $ | 11,598,858 |  |  |  | 100 | %

X
- Definition The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 430 -URI http://asc.fasb.org/topic&trid=2122452 + Details
Name: | us-gaap_DeferredRevenueDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration